Low-dose metformin treatment in the subacute phase improves the locomotor function of a mouse model of spinal cord injury.

ABSTRACT: Metformin, a first-line drug for type-2 diabetes, has been shown to improve locomotor recovery after spinal cord injury. However, there are studies reporting no beneficial effect. Recently, we found that high dose of metformin (200 mg/kg, intraperitoneal) and acute phase administration (immediately after injury) led to increased mortality and limited locomotor function recovery. Consequently, we used a lower dose (100 mg/kg, i.p.) metformin in mice, and compared the effect of immediate administration after spinal cord injury (acute phase) with that of administration at 3 days post-injury (subacute phase). Our data showed that metformin treatment starting at the subacute phase significantly improved mouse locomotor function evaluated by Basso Mouse Scale (BMS) scoring. Immunohistochemical s

SUBMITTER: Song WY 

PROVIDER: S-EPMC8354108 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature